You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
AstraZeneca
McKesson
Boehringer Ingelheim
Moodys

Last Updated: November 26, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,168,218

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,168,218 protect, and when does it expire?

Patent 8,168,218 protects RAYOS and is included in one NDA.

This patent has twenty-three patent family members in nineteen countries.

Summary for Patent: 8,168,218
Title:Delayed release tablet with defined core geometry
Abstract: A press-coated tablet comprising a core containing an drug substance, and a coating, the core being disposed within the coating such that the coating has a first thickness about an axis A-B and a thickness about an orthogonal axis X-Y, such that the coating about the axis X-Y is thicker than the coating about the axis A-B, and is adapted to provide a lag time of between about 2 to 6 hours during which substantially no drug substance is released.
Inventor(s): Vergnault; Guy (Kembs Loechle, FR), Grenier; Pascal (Kappelen, FR), Dragan; Christophe (Geispitzen, FR)
Assignee: Jagotec AG (Muttenz, CH)
Application Number:10/554,538
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,168,218
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Formulation; Device; Use;

Drugs Protected by US Patent 8,168,218

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Horizon Pharma Usa RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-003 Jul 26, 2012 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,168,218

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0309342.4Apr 24, 2003
PCT Information
PCT FiledApril 23, 2004PCT Application Number:PCT/IB2004/001693
PCT Publication Date:November 04, 2004PCT Publication Number: WO2004/093843

International Family Members for US Patent 8,168,218

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 512659   Start Trial
Australia 2004231362   Start Trial
Brazil PI0409652   Start Trial
Canada 2523158   Start Trial
China 102525993   Start Trial
China 1777412   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Baxter
Mallinckrodt
Colorcon
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.